Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release versus immediate-release tacrolimus after kidney allograft failure
2018-000652-18Phase 4Unknown
- Sponsor
- Imperial College London
- Start
- Jun 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tacrolimus in kidney transplant immunosuppression and Allosensitization (2 arms), sponsored by Imperial College London. Primary endpoint: Rate of de novo HLA antibodies or donor-specific antibodies at 24 months. Status: unknown.
02
Drugs
tacrolimus
03
Conditions
kidney transplant immunosuppressionAllosensitization
Beyond the preview
Go deeper on 2018-000652-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000652-18.